Clinical effect and mechanism of ozagrel sodium and vinpocetine combined with hyperbaric oxygen on acute cerebral infarction
10.3760/cma.j.cn311847-20200511-0019
- VernacularTitle:奥扎格雷钠和长春西汀联合高压氧治疗急性脑梗死患者的临床疗效及其作用机制
- Author:
Yun QIN
1
;
Guosun DENG
1
Author Information
1. 202150 上海，上海交通大学医学院附属新华医院崇明分院
- Publication Type:Journal Article
- Keywords:
Acute cerebral infarction;
Hyperbaric oxygen;
Ozagrel sodium;
Vinpocetine;
Curative effect
- From:
Chinese journal of nautical medicine and hyperbaric medicine
2020;27(4):444-448,462
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and mechanism of ozagrel sodium and vinpocetine combined with hyperbaric oxygen (HBO) in the treatment of acute cerebral infarction (ACI).Methods:A total of 172 patients with ACI, admitted to the Department of Neurology, Chongming Branch of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from December 2016 to June 2019, were selected and divided into groups A, B, C, and D by lottery with the ratio of 1∶1∶1∶1, i. e. 43 cases in each group. The group A was treated with ozagrel sodium, the group B was treated with vinpocetine, the group C was treated with vinpocetine and ozagrel sodium, and the group D was treated with vinpocetine, ozagrel sodium, and HBO. The clinical effects of the four groups were observed, and the National Institutes of Health Stroke Scale (NIHSS) and the Montreal Cognitive Assessment (MoCA) scores were compared. The levels of serum oxidative stress factors, i. e. malondialdehyde (MDA) and superoxide dismutase (SOD), the levels of brain injury response factors, i. e. macrophage colony stimulatory factor (M-CSF) and soluble intercellular adhesion molecule-1 (sICAM-1), and the level of vascular endothelial growth factor were measured by enzyme linked immunosorbent assay.Results:After 4 courses of treatment, the total effective rate of the group D (93.0%) was significantly higher than that of the group C (83.7%), and the total effective rate of the group C (83.7%) was significantly higher than those of the group B (74.4%) and the group A (72.1%) ( P<0.05). The NIHSS score of the group D was significantly lower than that of the group C, and the MoCA score of the group D was higher than that of the group C; the NIHSS score of the group C was significantly lower than those of the group A and the group B, and the MoCA score of the group C was higher than those of the group A and the group B, the differences were statistically significant ( P<0.05). The serum MDA level of the group D was significantly lower than that of the group C, and the SOD level of the group D was higher than that of the group C; the serum MDA level of the group C was significantly lower than those of the group A and the group B, and the SOD level of the group C was higher than those of the group A and the group B, the differences were statistically significant ( P<0.05). The serum levels of sICAM-1 and M-CSF in the group D were significantly lower than those in the group C, and the serum levels of sICAM-1 and M-CSF in the group C were significantly lower than those in the group A and the group B, with statistically significant differences ( P<0.05). The serum levels of BDNF and VEGF in the group D were significantly higher than those in the group C, and the serum levels of BDNF and VEGF in the group C were significantly higher than that in group A and the group B, with statistically significant differences ( P<0.05). Conclusion:Ozagrel sodium and vinpocetine combined with HBO can significantly improve the curative effect on ACI mainly by regulating the levels of brain injury response factors, oxidative stress factors, and neurovascular growth factor after ACI.
